NCT07361471 Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
| NCT ID | NCT07361471 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Jean Perrin |
| Condition | Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 55 participants |
| Start Date | 2026-01-22 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 55 participants in total. It began in 2026-01-22 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically. The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature. The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.
Eligibility Criteria
Inclusion Criteria: * Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment. * Corresponding to one of the two groups below: * Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy. * Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment * Affiliation to a social security scheme * Patient who signed the genetic consent form Exclusion Criteria: * Minor patient * Pregnant patient * Patient under guardianship or conservatorship * Patients who object to the collection of their medical/paramedical data * Patient for whom the center does not have biological material for genomic analysis (FFPE block) * Patient under administrative, judicial decision or AME (State Medical Aid)
Contact & Investigator
Tressie HERRMANN, MD
PRINCIPAL INVESTIGATOR
Centre Jean Perrin
Frequently Asked Questions
Who can join the NCT07361471 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07361471 currently recruiting?
Yes, NCT07361471 is actively recruiting participants. Contact the research team at judith.passildas@clermont.unicancer.fr for enrollment information.
Where is the NCT07361471 trial being conducted?
This trial is being conducted at Clermont-Ferrand, France.
Who is sponsoring the NCT07361471 clinical trial?
NCT07361471 is sponsored by Centre Jean Perrin. The principal investigator is Tressie HERRMANN, MD at Centre Jean Perrin. The trial plans to enroll 55 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.